Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
35.95
56.01
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Jiangsu Hengrui Pharmaceuticals Co Ltd
Jiangsu Hengrui Pharmaceuticals Co Ltd
Income from Continuing Operations
Jiangsu Hengrui Pharmaceuticals Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Income from Continuing Operations
¥5.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
14%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Income from Continuing Operations
¥3.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Income from Continuing Operations
¥3B
|
CAGR 3-Years
16%
|
CAGR 5-Years
19%
|
CAGR 10-Years
22%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Income from Continuing Operations
¥4.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Income from Continuing Operations
¥125.3m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Income from Continuing Operations
-¥780.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
Glance View
Jiangsu Hengrui Pharmaceuticals Co Ltd. is a leading player in the Chinese pharmaceutical industry, known for its strong emphasis on innovation and a commitment to enhancing patient care. Founded in 1993, Hengrui has grown rapidly, establishing itself as a key developer and manufacturer of a diverse range of medications, including oncology, analgesics, and anesthetics. The company stands out for its robust research and development framework, which has enabled it to introduce over 100 new drugs, several of which have gained global recognition. With a strategic focus on high-quality generics and innovative therapies, Hengrui caters to both domestic and international markets, positioning itself as a significant contender in the global pharmaceutical arena. Investors are particularly drawn to Hengrui's impressive financial performance and growth trajectory. The company boasts a well-established production capacity and a strong pipeline of drugs in various stages of clinical trials, which could pave the way for future revenue streams. Its commitment to compliance with international quality standards has opened doors to partnerships and market access around the world. As healthcare demands continue to rise, Hengrui's strategic investments in cutting-edge technology and expanded capabilities indicate not only resilience but also the potential for sustainable growth. With a consistent focus on innovation and a portfolio that addresses critical health needs, Jiangsu Hengrui Pharmaceuticals presents an attractive opportunity for investors looking to tap into the expanding pharmaceutical market in China and beyond.
See Also
What is Jiangsu Hengrui Pharmaceuticals Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
5.4B
CNY
Based on the financial report for Sep 30, 2024, Jiangsu Hengrui Pharmaceuticals Co Ltd's Income from Continuing Operations amounts to 5.4B CNY.
What is Jiangsu Hengrui Pharmaceuticals Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
14%
Over the last year, the Income from Continuing Operations growth was 31%. The average annual Income from Continuing Operations growth rates for Jiangsu Hengrui Pharmaceuticals Co Ltd have been -5% over the past three years , 2% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet
